Vinpocetine is a chemical substance synthesized from vincamine, a natural constituent found in the leaves of Vinca minor (lesser periwinkle).
Where is it found?
Vinpocetine is synthesized from vincamine, a constituent of the leaves of Vinca minor (lesser periwinkle)
Vinpocetine has been used in connection with the following condition (refer to the individual health concern for complete information):
| Science Rating | Health Concerns |
|---|---|
 | Age-related cognitive decline |
 | Stroke (intravenous vinpocetine only) Vertigo |
 | Alzheimer’s disease Memory Retinopathy Urinary incontinence |
| Reliable and relatively consistent scientific data showing a substantial health benefit. Contradictory, insufficient, or preliminary studies suggesting a health benefit or minimal health benefit. For an herb, supported by traditional use but minimal or no scientific evidence. For a supplement, little scientific support and/or minimal health benefit. | |
Who is likely to be deficient?
Vinpocetine is not an essential nutrient, so no deficiencies are possible.
How much is usually taken?
Research has typically used 30 to 60 mg per day of vinpocetine. Taking vinpocetine with food appears to dramatically improve its absorption. 1
Are there any side effects or interactions?
Studies on vinpocetine report no serious side effects with amounts up to 60 mg per day. 2 Vinpocetine has blood-thinning effects, 3 which suggests that people with bleeding disorders or who are taking anticoagulant or other blood-thinning medications should consult a doctor before taking vinpocetine. However, one study found no such interaction between vinpocetine and the anticoagulant drug warfarin. 4
Are there any drug interactions?
Certain medicines may interact with vinpocetine. Refer to drug interactions for a list of those medicines.
References
1. Lohmann A, Dingler E, Sommer W, et al. Bioavailability of vinpocetine and interference of the time of application with food intake. Arzneimittelforschung 1992;42:914–7.
2. Hindmarch I, Fuchs HH, Erzigkeit H. Efficacy and tolerance of vinpocetine in ambulant patients suffering from mild to moderate organic psychosyndromes. Int Clin Psychopharmacol 1991;6:31–43.
3. Osawa M, Maruyama S. Effects of TCV-3B (vinpocetine) on blood viscosity in ischemic cerebrovascular diseases. Ther Hung 1985;33:7–12.
4. Hitzenberger G, Sommer W, Grandt R. Influence of vinpocetine on warfarin-induced inhibition of coagulation. Int J Clin Pharmacol Ther Toxicol 1990;28:323–8.
Copyright 2007, Healthnotes, Inc., 1505 S.E. Gideon St., Suite 200, Portland, Oregon 97202, www.Healthnotes.com.
2006-09-07
